PDCD1 and cancer: Preliminary results from human trials of INDUCE-1 (NCT02723955), as an ICOS agonist antibody, showed that INDUCE-1 individually or in combination with PD-1 blocking antibodies such as pembrolizumab plays an essential role in cancer patients [51].